key: cord-0741043-biriw2fl
authors: Gniffke, Edward P; Harrington, Whitney E; Dambrauskas, Nicholas; Jiang, Yonghou; Trakhimets, Olesya; Vigdorovich, Vladimir; Frenkel, Lisa; Sather, D Noah; Smith, Stephen E P
title: Plasma from recovered COVID-19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay
date: 2020-08-15
journal: J Infect Dis
DOI: 10.1093/infdis/jiaa508
sha: 9990180fc6d34205c4221e21e0bfb4d79ae008d5
doc_id: 741043
cord_uid: biriw2fl

We present a microsphere-based flow cytometry assay that quantifies the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2). Plasma from 22 subjects who recovered from mild Coronavirus disease 2019 (COVID-19) and expressed anti-spike-trimer IgGs inhibited ACE2-spike binding to a greater degree than controls. The degree of inhibition correlated with anti-spike IgG levels, neutralizing titers in a pseudotyped lentiviral assay, and the presence of fever during illness. This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID-19 patients or vaccine recipients in a cell-free assay system.

A c c e p t e d M a n u s c r i p t 3 In late 2019 a novel SARS-like coronavirus (SARS-CoV-2) emerged in Wuhan, China[1].

The disease it causes, COVID-19, was declared a pandemic by the WHO in March 2020 [2] .

The cryo-electron microscoscopy structure of the spike glycoprotein, a viral surface protein that mediates cell entry of corona viruses, was solved by two groups [3, 4] , revealing a trimeric structure with either none or one of three receptor binding domains (RBDs) in the "up" state, capable of binding to its target. Similar to the 2003 SARS-CoV-1 virus, angiotensin converting enzyme 2 (ACE2) serves as the receptor necessary and sufficient for infection of the target cell [3] [4] [5] [6] [7] .

Nearly all patients who recover from SARS-CoV-2 infection produce IgM and IgG antibodies against the spike protein [7] [8] [9] , and a large number of serologic tests have been produced and marketed. However, it is unclear how effective the detected antibodies are at neutralizing viral activity. For example, a study measuring in vitro inhibition of ACE2-RBD binding in an ELISA-style assay showed only 3 of 26 (11.5%) recovered patients strongly inhibited binding [7] , while a larger study using pseudotyped lentivirus showed significant neutralization of infectivity in 165 of 175 (94.3%) recovered patients [9] . Indeed, human monoclonal antibodies that neutralize SARS-CoV-2 infectivity have been show to bind epitopes both within [7] and outside of the RBD [10] , so it is unclear if RBD-based measurements capture the full repertoire of inhibition of viral infectivity. While pseudoviruses that use the native spike protein to infect cells appear to identify antibodies that neutralize viral entry [9] , these assays are technically demanding, require specialized biosafety facilities, and may be difficult to scale up for population-level testing.

The objective of the current study was to design an overnight, cell-free assay to quantify a plasma sample"s ability to inhibit the binding of ACE2 to a recombinant COVID-19 spike protein. The assay is based on immunoprecipitation detected by flow cytometry (IP-FCM) technology, a highly sensitive and reagent-efficient method for detecting proteinprotein interactions using minimal amounts of biomaterial [11, 12] . We find that while only a minority of persons who have recovered from symptoms of COVID-19 produce antibodies that inhibit the RBD binding to ACE2 in vitro, almost all (22/24) produce antibodies that A c c e p t e d M a n u s c r i p t 4 potently inhibit the pre-fusion trimer binding to ACE2. Our results provide a new, relatively rapid and high-throughput method to quantify circulating levels of functional anti-SARS-CoV-2 antibodies, and suggest that the entire spike protein as opposed to the RBD should be used when characterizing SARS-CoV-2 immunity.

Human Samples: Negative controls consisted of banked samples collected from healthy adults prior to January 2020. Controls ranged in age from 19 to 66 years (median 37) and 18/30 were female (60%). Samples from adults recovered from COVID19 came from the Seattle Children"s Research Institute SARS2 Recovered Cohort. All subjects reported testing PCR+ for SARS-CoV-2. The day of sample collection ranged from 14 to 73 days postsymptom-onset, with a median of 36 days. All SARS-CoV-2 infections were symptomatic, ranging from very mild to moderate illness; no subjects required hospitalization or supplemental oxygen. 12/24 subjects experienced fever and 16/24 experienced cough. All subjects provided informed consent, and parent studies were IRB approved through Fred Hutchison Cancer Research Center or Seattle Children"s Hospital.

Protein purification: The RBD construct (AA 319-541; UniProt P0DTC2) was cloned into the pCDNA3.4 protein expression vector with an 8XHIS-tag and tandem aviTag. The SARS-CoV-2 trimer [3] and ACE2 constructs were generously provided by Dr. Jason McLellan (University of Texas at Austin) and Dr. Barney Graham (National Institutes of Health) [3] .

Proteins were expressed in 293F cells in antibiotic free, serum free media as previously described [13] . Briefly, DNA was transfected using PEI Max and grown for 5 days at 37C, 5% CO2. The recombinant proteins were purified by NiNTA affinity chromatography and IgG Detection with IP-FCM: IP-FCM was performed as previously described [11, 12] .

Plasma from both SARS-CoV-2 positive and negative adults was heated to 56 °C for 1 hour, then spun at 13,000 x g for 10 minutes at 4 °C. The supernatant was diluted (1:1000 unless 

Full length SARS-CoV-2 S protein was used to create pseudo-typed lentivirus as previously described [15] with slight modifications. Plasmids encoding S and HIV-1 structural genes were co-transfected into 293T cells using PEI Max and grown at 32C for 3 days prior to harvesting supernatants. 293 cells stably expressing ACE2 were plated in 96-well plates at a density of 10 4 / well 24 hours prior to viral challenge, and polybrene was added at 2ug/ml for 30 min prior to viral challenge. Heat inactivated plasma from COVID+ subjects or pre-COVID controls were serially diluted from 1:50 -1:109,350 and co-incubated with virus for 60 min prior to plating on cells. The plates were incubated at 37C for 65 hours, the media removed, and 100 ul of Steady Glo (Promega) added. Relative light unit (RLU) values were read on a luminometer, and the percent neutralization was calculated as (RLU virus -RLU virus+plasma ) / (RLU virus ) X 100. We selected a subset of total samples to span the range of inhibition for both COVID+ and control samples, all samples analyzed are reported. IC50 values were extrapolated from non-linear regression model, and represent the reciprocal plasma dilution at which 50% viral inhibition was recorded.

Patient plasma was diluted 1:50 in Fly-P Buffer and incubated with 2ul of RBD-or trimercoupled carboxy-modified latex (CML, see supplementary material) beads overnight at 4C. The next day, the beads were pelleted at 13,000 RPM for 1 minute, removed and discarded.

A 2ul aliquot of plasma was reserved, and 2ul of new, RBD-or trimer-coupled CML beads were added. This process was repeated for a total of 3 overnight depletions. On the 4 th day, 25ul of the RBD-or trimer-depleted plasma was run on the ACE2-Spike binding assay, as Technical replicates were averaged and data were imported to Prism 8.0 (GraphPad).

Comparisons between two groups were made using two-tailed t-tests, and among three groups with one-way ANOVA followed by post-hoc tests comparing all columns, corrected for multiple comparisons by the Tukey method. Correlations and half maximal effective concentrations (EC50) were determined using simple linear regressions or 4-parameter logistic regressions with default settings, and r 2 values are reported.

Luminex MagPlex microspheres coupled to either the recombinant RBD fragment [16] or a spike trimer construct [3] were incubated with plasma specimens, and then with antihuman IgG antibodies conjugated to phycoerythrin (PE) ( Figure 1A ). SARS-CoV-2 antibodies were stringently defined as "positive" at a median fluorescence intensity (MFI) greater than the highest control value plus 5 standard deviations (dashed lines in Figure   1B ,C). Using this definition, 22/24 (91.6%) COVID+ samples were classified as "seropositive" for trimer reactivity, and 21/24 (87.5%) for RBD. There was a moderate correlation between RBD and trimer immunoreactivity ( Figure 1D , r 2 = 0.64). During assay development, we performed experiments using carboxy-modified latex (CML) microspheres on a subset of the total plasma samples. We present those data and CML-specific methods in Figure S1 to compare two different microsphere types, and to note the good correlation between trimer (r 2 = 0.85) and RBD (r 2 = 0.75) values for the 12 samples that were measured using both microsphere types ( Figure S1F, G) . While we chose to use MagPlex beads due to higher average fluorescence values, lower non-specific binding, and the availability of magnetic plate washing, CML beads are also a viable, less expensive option To quantify the ability of convalescent plasma to inhibit the spike binding to ACE2, we coupled human ACE2 protein to MagPlex microspheres and incubated with biotinylated RBD or trimer, followed by incubation with Streptavidin-PE (Figure 2A) . Both trimer and RBD demonstrated strong binding to ACE2 ( Figure 2B,C) , and the EC 50 was used to determine A c c e p t e d M a n u s c r i p t 9 the dilution of spike proteins added to the binding inhibition assay. As a specificity control, unlabeled human ACE2 inhibited binding of both RBD and trimer by >90% ( Figure 2D ). After optimizing the plasma dilution ( Figure S2C,D) , we evaluated the same plasma samples for their ability to inhibit the ACE2-Spike interaction. Analyzed as a group, the MFI of control plasma was not significantly different than no-plasma controls in the trimer or RBD assays ( Figure 3A However, when data were examined by individual, important differences emerge between the trimer and RBD-based assays. For the trimer inhibition assay, all 22 plasma samples that tested positive for anti-trimer IgG (as defined above) showed greater inhibition than any of the negative control samples ( Figure 3A) . Conversely, in the RBD assay, only 9/24 samples showed greater inhibition than the highest negative control, despite 21/24 samples being sero-positive ( Figure 3B ). Moreover, in the trimer assay there was a strong correlation between the amount of anti-trimer IgG and the percent inhibition among COVID+ (r 2 = 0.79) but not negative control (r 2 = 0.04) samples ( Figure 3C ). There was no such correlation in the RBD assay (COVID+ r 2 = 0.047, negative control r 2 = 0.034, Figure 3D ).

There was also no correlation between the percent inhibition of plasma samples in the RBD and trimer assays (COVID+ r 2 = 0.036, pre-COVID r 2 = 0.011). Experiments performed using CML microspheres during assay development using a subset of the total plasma showed similar results, although with a smaller dynamic range ( Figure S2) , and there was good correlation between trimer values for the 12 samples that were measured using both microsphere types (r 2 = 0.85, Figure S2K ).

The trimer has several modifications, including a fibritin trimerization domain and elimination of the Furin cleavage site [3, 17] that could potentially induce artifacts. We A c c e p t e d M a n u s c r i p t 10 selected a subset of COVID+ samples that spanned the range of the trimer inhibition assay and performed a neutralizing titer assay using a pseudotyped lentivirus to determine an IC 50 for each sample. Nine of 13 COVID+ samples (9/11 IgG+ samples) showed IC 50 values greater than the minimum detectable value (1:50), which correlated with anti-trimer IgG levels ( Figure 4A , r 2 = 0.60). Among all COVID+ samples, there was a moderate correlation between IC 50 value and percent inhibition in the trimer inhibition assay ( Figure 4B , r 2 = 0.52); there was no correlation for the RBD inhibition assay ( Figure 4C , r 2 = 0.02). Samples with trimer-inhibition of less than 60% showed a range of IC 50 values (<1:50 to 1:830), while all samples above 60% inhibition showed IC50 plasma dilutions of at least 1:77, to a maximum of 1:2,277. It is unclear if the differences between the two datasets represent limitations of the trimer inhibition assay, the lentiviral pseudovirus assay, or both. However, these data demonstrate that, at least for strongly inhibiting samples, there is moderate agreement between the cell-based and microsphere-based assays.

To determine if inhibition of binding was caused by antibodies binding within or outside of the RBD, we next depleted the plasma of one negative control and three COVID+ samples by incubating with large numbers of trimer-or RBD-conjugated CML beads for three consecutive overnight incubations until the levels of IgG detected in the plasma plateaued ( Figure 5A, B) , and ran the trimer-ACE2 inhibition assay on the depleted plasma.

Inhibition was partially (although non-significantly) reduced by RBD depletion, and was reduced to a greater degree by trimer depletion ( Figure 5C , ANOVA F (2, 6) =8.51, p=0.018, Not depleted vs. RBD depleted p = 0.11, Not depleted vs. trimer depleted p = 0.015, RBD depleted vs. trimer depleted = 0.30 by Tukey post-hoc test). Thus, even though RBD depletion was more efficient than trimer depletion in terms of reduction in detectable anti-SARS2 IgG (RBD avg. depleted MFI 3845 vs 3629 control, trimer avg. depleted MFI 16, 481 vs 1545 control, Fig 5A,B) , trimer depletion was more effective at removing the neutralizing capacity of the plasma. These data suggest that spike trimer neutralizing antibodies bind both within and outside of the RBD.

A c c e p t e d M a n u s c r i p t 11 COVID+ subjects were between 28 and 63 years of age (median 42 years of age) and were 71% (17/24) female. Age was associated with a trend toward increased anti-trimer IgG and inhibition (per year MFI difference: 3,816, p=0.09; inhibition difference: 1%, p=0.07), although this may have been driven by the two subjects with negative anti-SARS2 IgG, who were both relatively young (28yr, 41yr). Sex, days since symptom onset, and cough were not associated with anti-trimer IgG or inhibition. In contrast, fever was strongly associated with both anti-trimer IgG and inhibition in both unadjusted (MFI difference: 103,982, p=0.007; inhibition difference: 20%, p=0.04) and adjusted models that accounted for subject age, sex, and days from symptom onset (adjusted MFI difference: 103,530, p=0.01; adjusted inhibition difference: 20%, p=0.03). Both anti-SARS2 IgG-negative subjects had very mild disease without fever, and follow-up testing using the commercial Cellex platform as well as laboratory-developed ELISAs using spike and nucleoprotein (n=3 different labs) failed to detect anti-SARS2 antibodies.

The acquisition of antiviral immunity to SARS-CoV-2 will be a critical prerequisite for a return to normalcy from the current pandemic. As of this writing, it is still unclear if infection or vaccination will lead to robust, long-lasting immunity [18] . While some early data suggested ineffective immune responses, such as low levels of ACE2-RBD inhibition by convalescent serum in an ELISA-style binding assay [7] or the detection of viral RNA in recovered patients [19] , more recent data suggest effective anti-viral antibody activity in the majority of patients. For example, serum from 94% of recovered patients effectively inhibited pseudotyped lentiviral infection of susceptible cells [9] , similar to our rates; four Rhesus Macaques experimentally infected with SARS-CoV-2 were resistant to re-infection [20] ; and a recent report suggests that the viral RNA detected in recovered patients is not associated with an active infection or the ability to transmit COVID-19 [21] . Our data, demonstrating in vitro inhibition of ACE2-trimer binding in 92% of recovered patients, adds to this growing A c c e p t e d M a n u s c r i p t 12 literature that collectively suggest that infection with SARS-CoV-2 results in robust immunity, at least in the short-term.

There are several limitations to our study that should be noted. We focus solely on binding of ACE2 to the spike protein and ignore other potential antigens or other immune mechanisms such as inhibition of protease cleavage that might prevent viral entry into the cell. While the correlation between microsphere-based ACE2-Trimer binding inhibition and cell-based pseudovirus neutralization was moderate, two samples that showed <60% was added to the trimer or RBD binding assay (red histograms), which resulted in a >90% reduction in MFI compared to binding assays without soluble ACE2 (black histograms). RBD or trimer was omitted to establish background MFI (grey histograms). 

Author Contributions SEPS conceived the study. EPG, SEPS, NS and WH planned experiments. EPG performed all microsphere-based experiments. ND, VV, and OT designed, expressed and purified recombinant proteins and performed QC and antigenic properties, and conducted neutralization assays. YJ, WH and LF conducted the Seattle Children"s SARS2 Recovered Cohort sample collection and provided samples and deidentified patient data. EPG, SEPS, WH and DNS analyzed the data

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

WHO Declares COVID-19 a Pandemic

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

Antibody responses to SARS-CoV-2 in patients with COVID

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv

A human monoclonal antibody blocking SARS-CoV-2 infection

IP-FCM Measures Physiologic Protein-Protein Interactions Modulated by Signal Transduction and Small-Molecule Drug Inhibition

IP-FCM: Immunoprecipitation Detected by Flow Cytometry

Oral Immunization with HIV-1 Envelope SOSIP trimers elicits systemic immune responses and cross-reactive anti-V1V2 antibodies in nonhuman primates

Quantification of Protein Interaction Network Dynamics using Multiplexed Co-Immunoprecipitation

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

A serological assay to detect SARS-CoV-2 seroconversion in humans

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions

Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China

Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2. bioRxiv. Cold Spring Harbor Laboratory

COVID-19 Reinfection: Myth or Truth?